法洛四联症患者植入ICD的长期随访:DAI-T4F全国注册研究
该法国全国注册研究纳入165例植入了ICD的法洛四联症患者,中位随访6.8年,47.3%的患者接受了至少一次恰当ICD治疗,年发生率为10.5%。43.0%的患者出现ICD相关并发症,包括不恰当放电和导线功能障碍。QRS碎裂是恰当ICD治疗的独立预测因素,将其加入现有标准可提高风险分层的区分度。
要点
- 法洛四联症ICD患者恰当治疗年发生率高,一级预防患者亦不低。
- ICD相关并发症负担重,需谨慎选择植入候选人。
- QRS碎裂可独立预测恰当ICD治疗,联合现有标准改善风险分层。
核心结论
- 法洛四联症ICD患者恰当治疗发生率高,包括一级预防患者;ICD相关并发症负担显著,需谨慎选择候选人;结合QRS碎裂等简易标准可能改善风险分层。
研究设计与样本
- 法国全国注册研究,2010年由法国国家健康与医学研究所发起,纳入所有植入了ICD的法洛四联症患者,共165例,来自40个中心,平均年龄42.2±13.3岁,男性占70.1%,其中104例(63.0%)为二级预防。
主要发现
- 中位随访6.8年(IQR 2.5-11.4),78例(47.3%)患者接受了至少一次恰当ICD治疗,年发生率为10.5%(一级预防7.1%,二级预防12.5%,P=0.03)。
- 71例(43.0%)患者出现至少一次ICD并发症,包括42例(25.5%)不恰当放电和36例(21.8%)导线功能障碍。
- 一级预防患者中,61例(37.0%)的恰当ICD治疗年发生率随指南推荐风险因素数目(0、1、2、≥3个)分别为4.1%、5.3%、9.5%、13.3%。
- QRS碎裂是恰当ICD治疗的唯一独立预测因素(HR 3.47,95%CI 1.19-10.11),将其加入现有标准模型使5年时间依赖AUC从0.68提高至0.81(P=0.006)。
- 合并充血性心力衰竭或左心室射血分数降低的患者非心律失常性死亡或心脏移植风险更高(HR 11.01,95%CI 2.96-40.95)。
关键数值与推荐
- 恰当ICD治疗年发生率:总体10.5%,一级预防7.1%,二级预防12.5%(P=0.03)。
- 一级预防患者按指南推荐风险因素0、1、2、≥3个,恰当ICD治疗年发生率分别为4.1%、5.3%、9.5%、13.3%。
- QRS碎裂预测恰当ICD治疗的HR为3.47(95%CI 1.19-10.11)。
- 模型加入QRS碎裂后5年时间依赖AUC从0.68升至0.81(P=0.006)。
- 心力衰竭或左室射血分数降低者非心律失常性死亡/心脏移植的HR为11.01(95%CI 2.96-40.95)。
临床怎么用
- 对法洛四联症患者植入ICD前应充分评估恰当治疗获益与并发症风险,尤其是一级预防患者。
- QRS碎裂可作为风险分层的辅助指标,结合现有指南推荐标准优化患者选择。
- 合并心力衰竭或左室射血分数降低的法洛四联症ICD患者需关注非心律失常性死亡及心脏移植风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, and sudden cardiac death represents an important mode of death in these patients. Data evaluating the implantable cardioverter defibrillator (ICD) in this patient population remain scarce. METHODS: A Nationwide French Registry including all patients with tetralogy of Fallot with an ICD was initiated in 2010 by the French Institute of Health and Medical Research. The primary time to event end point was the time from ICD implantation to first appropriate ICD therapy. Secondary outcomes included ICD-related complications, heart transplantation, and death. Clinical events were centrally adjudicated by a blinded committee. RESULTS: A total of 165 patients (mean age, 42.2±13.3 years, 70.1% males) were included from 40 centers, including 104 (63.0%) in secondary prevention. During a median (interquartile range) follow-up of 6.8 (2.5-11.4) years, 78 (47.3%) patients received at least 1 appropriate ICD therapy. The annual incidence of the primary outcome was 10.5% (7.1% and 12.5% in primary and secondary prevention, respectively; P=0.03). Overall, 71 (43.0%) patients presented with at least 1 ICD complication, including inappropriate shocks in 42 (25.5%) patients and lead dysfunction in 36 (21.8%) patients. Among 61 (37.0%) patients in primary prevention, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patients with, respectively, 0, 1, 2, or ≥3 guidelines-recommended risk factors. QRS fragmentation was the only independent predictor of appropriate ICD therapies (hazard ratio, 3.47 [95% CI, 1.19-10.11]), and its integration in a model with current criteria increased the 5-year time-dependent area under the curve from 0.68 to 0.81 (P=0.006). Patients with congestive heart failure or reduced left ventricular ejection fraction had a higher risk of nonarrhythmic death or heart transplantation (hazard ratio, 11.01 [95% CI, 2.96-40.95]). CONCLUSIONS: Patients with tetralogy of Fallot and an ICD experience high rates of appropriate therapies, including those implanted in primary prevention. The considerable long-term burden of ICD-related complications, however, underlines the need for careful candidate selection. A combination of easy-to-use criteria including QRS fragmentation might improve risk stratification. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03837574.
引用
- Waldmann V, Bouzeman A, Duthoit G, et al. Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry. Circulation. 2020. PMID: 32998542. doi:10.1161/CIRCULATIONAHA.120.046745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。